NorthStar Medical Radioisotopes and IBA Sign Agreement for

NorthStar is additional increasing commercial-scale home radioisotope manufacturing capabilities utilizing IBA’s environmentally preferable Rhodotron^® accelerator know-how

Louvain-La-Neuve, Belgium, and BELOIT, Wisconsin, USA September 20, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world chief in particle accelerator know-how, and NorthStar Medical Radioisotopes, LLC, a world innovator within the improvement, manufacturing and commercialization of radiopharmaceuticals used for medical imaging and therapeutic purposes, right now introduced a brand new settlement below which NorthStar will buy two extra Rhodotron^® TT300 HE electron beam accelerators, and the related beamlines, from IBA for the manufacturing of molybdenum-99 (Mo-99).

The buy marks a complete of 5 Rhodotron^® accelerators that NorthStar has bought from IBA so far. NorthStar beforehand bought two electron beam accelerators from IBA in 2019 for the manufacturing of Mo-99, and bought a 3rd accelerator in 2021 for manufacturing of the therapeutic radioisotope actinium-225 (Ac-225). The extra accelerators can be used to additional broaden NorthStar’s commercial-scale radioisotope manufacturing capabilities at its Beloit, Wisconsin headquarters. All NorthStar manufacturing processes make use of revolutionary, environmentally preferable know-how and are non-uranium primarily based.

NorthStar’s first Accelerator Production facility growth in Beloit is nearing completion and shifting to the ultimate part of actions required for licensure and FDA approval. Both accelerators are working at full energy and present process ultimate testing. Equipment within the adjoining Isotope Processing facility has been put in and present process ultimate testing. Construction of NorthStar’s devoted Actinium-225 Production facility can be effectively underway, with cargo of the third IBA Rhodotron^® accelerator anticipated by the tip of 2022.

“NorthStar continues to invest in the future of nuclear medicine using innovative technology to advance environmentally sustainable radioisotope production, and the purchase of these additional accelerators marks another milestone of our highly productive relationship with IBA,” stated Stephen Merrick, Chief Executive Officer of NorthStar. “IBA has demonstrated extensive commercial expertise and excellent performance in delivering electron beam accelerators for our Mo-99 production expansion program, and in the design and custom-build of our Ac-225 accelerator. We are proud that IBA is a partner in helping to make these important diagnostic imaging and therapeutic radioisotope products available to advance patient health, and look forward to continuing to work with them.”

Olivier Legrain, Chief Executive Officer of IBA commented, “We are delighted to sign this latest agreement with NorthStar Medical Radioisotopes and to continue to deliver innovative solutions for reliable radioisotope supply. IBA’s Rhodotron^® accelerators provide the most advanced electron accelerator technology in the world, enabling a non-uranium based and highly efficient method for producing medical radioisotopes such as Mo-99, Ac-225 and Cu-67. We look forward to continuing to work with NorthStar to advance research and help patients.”

***ENDS***

About IBA
IBA (Ion Beam Applications S.A.) is the world chief in particle accelerator know-how. The firm is the main provider of kit and providers within the area of proton remedy, thought of to be essentially the most superior type of radiation remedy accessible right now. IBA can be a number one participant within the fields of commercial sterilization, radiopharmaceuticals and dosimetry. The firm, primarily based in Louvain-la-Neuve, Belgium, employs roughly 1,600 folks worldwide. IBA is a licensed B Corporation (B Corp) assembly the best requirements of verified social and environmental efficiency.
                 
IBA is listed on the pan-European inventory trade EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More info may be discovered at: www.iba-worldwide.com.

About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage nuclear drugs firm that manufactures and distributes diagnostic and therapeutic radioisotopes and radiopharmaceuticals. The Company’s proprietary state-of-the-art know-how and confirmed administration staff have propelled it to the forefront of U.S. medical radioisotope manufacturing as the only home producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m (Tc-99m), the usual of care in diagnostic imaging to evaluate the extent and severity of coronary heart illness and most cancers. NorthStar’s distinctive Mo-99 manufacturing course of is non-uranium primarily based and environmentally pleasant. NorthStar is increasing its industry-leading place within the rising space of therapeutic radioisotopes, that are utilized in focused radiopharmaceutical remedy to deal with most cancers, respiratory and different illnesses. Using first-in-kind and environmentally-sound electron accelerator know-how, NorthStar is poised to be the primary commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67). NorthStar additionally collaborates with different firms within the improvement of radiopharmaceuticals. For extra details about NorthStar’s complete radiopharmaceutical portfolio, go to: www.northstarnm.com.

CONTACTS

• 20220920-NorthStar-IBA_2_accelerators_EN